Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution
Date:11/6/2009

DETROIT, Nov. 6 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has launched ketorolac tromethamine ophthalmic solution, 0.5% following a final approval from the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA) for generic Acular® ophthalmic solution on the first day following patent expiration. This strength of ketorolac is therapeutically equivalent to Acular® Ophthalmic Solution, 0.5%, from Allergan, Inc. Ketorolac tromethamine ophthalmic solution is indicated for temporary relief of ocular itching due to seasonal allergic conjunctivitis. Ketorolac tromethamine ophthalmic solution is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction. Acular® ophthalmic solution has annual sales of approximately $40 million in the US.

Acular® is a registered trademark of Allergan, Inc.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "believe" or "expect" and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Part I, Item 1A of our most recent Form 10-K, and include but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, material litigation from product recalls, the purported class action lawsuits alleging federal securities laws violations, delays in returning the Company's products to market, including loss of market share, increased reserves against the FDA-seized inventory, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.

SOURCE Caraco Pharmaceutical Laboratories, Ltd.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution
2. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2010
3. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
4. Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
6. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
7. Trubion Pharmaceuticals, Inc. Reports Third Quarter and Nine Months 2009 Financial Results
8. Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results
9. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
10. Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
11. Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ... fourth quarter and full year ended December 31, 2015. ... was a transformational year for Vanda with the continued ... market approval of HETLIOZ for Non-24," said Mihael H. ... Fanapt to our U.S. product portfolio builds on this ...
(Date:2/10/2016)... , February 10, 2016 ... Analyzers (Liquid & Gas), and Spectroscopy Market by Industry (Oil ... Beverage, Pulp & Paper, Metal & Mining, and Others), ... MarketsandMarkets, the global market is expected to grow to ... of 8.6% between 2015 and 2020. Browse ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... As part of their 2015 end of year ... Table Foundation (MDRTF), has gifted $10,000 to University of Chicago to support ovarian cancer ... Cundiff. , “We are honored to support a promising young investigator from Dr. Lengyel’s ...
(Date:2/10/2016)... ... February 10, 2016 , ... The ... World Molecular Imaging Congress (WMIC), will be held in New York City, NY ... “Imaging Biology…Improving Therapy.” The congress will highlight and emphasize how imaging reveals a ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Early this week, ... and raise awareness of Nestlé KITKAT as the first global confectionery brand sourced from ... cocoa farmers and the quality of their product, through activities that focus on better ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... care communications company offering education, research and medical media, has launched ... working in infectious diseases. , As the all-inclusive resource for infectious disease ...
(Date:2/10/2016)... Walton Beach, Florida (PRWEB) , ... February 10, ... ... the innovative weather-forecasting company is unveiling its revolutionary new 2.0 version at the ... platform, MetLoop has “put the power of the world's most advanced weather technology ...
Breaking Medicine News(10 mins):